Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current burden and health care utilization of inflammatory bowel disease in the United States, 2023-2024.

Intestinal research·2026
Same author

Risk Assessment of Cardiovascular Disease-related Mortality in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical and molecular hepatology·2026
Same author

Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease.

Expert review of gastroenterology & hepatology·2026
Same author

Impact of Fatigue on Patient-Reported Outcomes and Work Productivity in Chronic Hepatitis B and C: Insights From a Multinational Registry Study.

Journal of viral hepatitis·2026
Same author

Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib.

Liver cancer·2026
Same author

Burden of Cardiovascular Complications in Steatotic Liver Disease in the United States.

Clinical and molecular hepatology·2026
Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

6.6K

Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Al B Benson1, Michael I D'Angelica2, Thomas Abrams3

  • 11Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Journal of the National Comprehensive Cancer Network : JNCCN
|September 10, 2025
PubMed
Summary
This summary is machine-generated.

The NCCN Guidelines offer expert recommendations for biliary tract cancers (BTCs), focusing on adjuvant chemotherapy, chemoradiation, and systemic treatments for advanced stages. These guidelines ensure comprehensive care for gallbladder, intrahepatic, and extrahepatic cholangiocarcinoma patients.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

691

Related Experiment Videos

Last Updated: Jun 27, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

6.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

691

Area of Science:

  • Oncology
  • Gastroenterology
  • Clinical Practice Guidelines

Background:

  • Biliary tract cancers (BTCs), including gallbladder, intrahepatic, and extrahepatic cholangiocarcinoma, require standardized management strategies.
  • The National Comprehensive Cancer Network (NCCN) convenes multidisciplinary expert panels to develop evidence-based guidelines.
  • Regular updates ensure guidelines reflect the latest data on diagnosis and treatment.

Purpose of the Study:

  • To present the NCCN Guidelines for the comprehensive care of patients with biliary tract cancers.
  • To detail recommendations for adjuvant chemotherapy and chemoradiation for resectable BTCs.
  • To outline systemic treatment options for patients with advanced or metastatic BTCs.

Main Methods:

  • The NCCN Guidelines are developed through a consensus process involving a multidisciplinary panel of oncology experts.
  • The panel reviews new research, clinical trial data, and treatment outcomes annually.
  • Recommendations are based on the best available scientific evidence and expert clinical judgment.

Main Results:

  • The guidelines provide specific recommendations for the evaluation and multidisciplinary management of BTCs.
  • Adjuvant chemotherapy and chemoradiation strategies are outlined for resectable disease.
  • Systemic therapy options, including targeted therapy and immunotherapy, are discussed for advanced BTCs.

Conclusions:

  • The NCCN Guidelines offer a framework for optimal, evidence-based care for patients with biliary tract cancers.
  • Adherence to these guidelines can improve patient outcomes through standardized and comprehensive treatment approaches.
  • Ongoing evaluation of emerging therapies is crucial for advancing BTC management.